drugset / Trial / NCT00096837

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837

Phase 2 Completed 25 enrolled Pharmacyclics LLC.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject motexafin gadolinium Diagnostic / imaging agent

Indications